• The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate AI-based ECG Algorithms
• The collaboration is focused on building next-generation, personalized AI-ECG algorithms for wellness and clinical applications, including assessing heart attack risk
• HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System

HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions.

The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate high value, AI-based ECG algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management. 

The importance of developing and validating AI-ECG algorithms continues to grow as cardiovascular disease remains a leading cause of mortality worldwide. Traditional ECG interpretation can be time consuming and subject to variability, while AI-driven approaches offer the potential to enhance accuracy, reduce diagnostic delays and uncover subtle patterns that may not be easily recognized by clinicians. 

At the core of this collaboration is the combination of HeartBeam’s proprietary signal acquisition technology and Mount Sinai’s clinical expertise. HeartBeam’s unique ability to generate longitudinal, high-fidelity synthesized 12-lead ECG datasets from patients in the home setting—data that has historically been inaccessible to AI development – creates a foundation for developing increasingly personalized algorithms earlier in the care journey and enabling 12-lead ECG assessments in real-world settings.

By leveraging longitudinal, real-world synthesized 12-lead ECG data rather than isolated clinical snapshots, the collaboration has the potential to significantly expand the addressable market for AI-driven cardiac monitoring. The collaboration could unlock new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring—further reinforcing HeartBeam’s position as a leader in cardiac intelligence platforms.

HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System, which is the first cable-free, high-fidelity ECG system capable of capturing the heart’s electrical signals from three non-coplanar dimensions for arrhythmia assessment. The system has received U.S. Food and Drug Administration (“FDA”) clearance for arrhythmia assessment and is designed to provide a more comprehensive view of cardiac electrical activity than traditional single-lead devices, enabling richer datasets for analysis and interpretation. This multidirectional signal capture is particularly valuable for AI applications, as more robust data inputs can improve algorithm performance and reliability.

Moreover, the company’s technology integrates embedded electrodes into a compact, handheld device, allowing patients to record ECG signals wherever they are without adhesive patches or wires. This design simplifies use while maintaining clinical-grade signal quality, making it well-suited for remote monitoring. 

The collaboration with Mount Sinai builds on this foundation by providing access to clinical datasets necessary to train and validate AI models. Validation is a critical step in the development of medical AI, ensuring that algorithms perform reliably across diverse patient populations and clinical scenarios. Without rigorous validation, even promising AI tools may struggle to gain regulatory approval or clinical adoption. By working with a leading academic medical center, HeartBeam is positioning its technology within a framework that prioritizes clinical rigor and real-world applicability.

Beyond improving accuracy, AI-ECG algorithms have the potential to transform how cardiac care is delivered. Remote monitoring platforms that incorporate AI can enable continuous assessment of patients, allowing clinicians to detect changes earlier and intervene before conditions worsen. This approach aligns with broader healthcare trends emphasizing preventive care, decentralized assessments and the integration of digital technologies into routine clinical practice.

HeartBeam’s collaboration also reflects a strategic effort to expand the capabilities of its platform beyond its current indications. As AI models become more sophisticated, they have potential to support new use cases such as predicting future cardiac events, identifying ischemic changes or stratifying patient risk. These capabilities could open additional pathways for growth and broaden the clinical impact of the company’s technology. As HeartBeam continues to develop and validate AI-driven solutions in partnership with leading institutions, its efforts underscore the growing convergence of medical devices, data analytics and artificial intelligence in shaping the future of cardiovascular care.

For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising.

• CMX Gold & Silver Corp., an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, sees compelling prospects for unexplored areas of the project, magnified by the growing value of silver
• According to J.P. Morgan Global Research, silver prices are projected to average $81/oz in 2026, double their average in 2025, encouraging aggressive exploration of the historically productive but largely unexplored site
• In January 2026, the company commenced a non-brokered private placement financing for aggregate gross proceeds of up to CAN$2,000,000

CMX Gold & Silver (CSE: CXC) (OTC: CXXMF), an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, recognizes that global demand and geopolitical factors are further boosting silver prices. To capitalize on this growth, the company is moving forward with the exploration of its flagship Clayton Silver project in Idaho, a 1,028-acre property with 29 patented mining claims, 2 patented mill sites, and 20 unpatented claims (https://ibn.fm/6SkLE).

The mine once ranked as the most active underground mine in the district, producing silver, along with lead, zinc, minor gold, and copper (https://ibn.fm/j21FN). However, the Clayton mine was never fully explored. It was only mined along a single vein because no more ore was needed for the small mill operation. But the site represents a dolomite limestone deposit, uplifted when the mountains were formed. Geology suggests a high probability that there are other undiscovered cracks in the overall deposit, cracks into which geothermal fluids would have flowed and deposited minerals, just as they were in the original producing vein. As a result, the company sees it as highly improbable that the single partially mined vein was the only silver vein there.

Today, despite the typical ups and downs of mineral prices, the surge in silver prices, along with the property’s promising geology and history, is driving the company’s Clayton Silver Mine activity. According to J.P. Morgan Global Research, silver prices rose by over 130% in 2025, primarily driven by industrial demand along with uncertainty over tariff regulations and global economic pressures on currencies. According to the research conducted, silver prices are expected to average $81/oz in 2026, double their average in 2025 (https://ibn.fm/CiZLA).

Given silver’s critical role in multiple industrial processes, along with international economic stresses on currencies, silver demand is expected to continue rising longer-term, exacerbating a large structural supply deficit. Today, industrial applications account for greater than 60% of total demand, with requirements relentlessly increasing for solar panels, AI buildout and military applications (missiles, etc.). All of this places CMX in a strong position for financing an impactful exploration program.

In January 2026, the company announced a non-brokered private placement financing for aggregate gross proceeds of up to CAN$2,000,000. The proceeds are for a geophysical survey and an initial diamond-drilling program on the property, bringing life to a mine that was never fully explored (https://ibn.fm/QoVms).

The company is off to a great start in 2026 and is on track to have its best year yet.

For company information, visit the company’s website at www.CMXGoldandSilver.com.

NOTE TO INVESTORS: The latest news and updates relating to CXXMF are available in the company’s newsroom at https://ibn.fm/CXXMF

• A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation
• Proton therapy’s ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida
• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary of LIXTE and developer of the electronically controlled LiGHT proton therapy platform

For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The core limitation persisted: photon beams pass through the body, leaving an exit dose of radiation in tissue beyond the tumor. The question oncologists repeatedly returned to was not whether this collateral exposure mattered, but how much it mattered over a patient’s lifetime. A landmark study published in The Lancet in December 2025 offered some of the clearest evidence yet, and the findings are beginning to influence how cancer treatment infrastructure is being planned.

A Survival Gap That Changes Conversation

The University of Texas MD Anderson Cancer Center led the largest randomized Phase III trial to date comparing proton therapy to traditional radiation therapy in patients with oropharyngeal cancer. The study enrolled 440 patients across 21 proton centers in the U.S. and tracked outcomes over five years.

Patients treated with intensity-modulated proton therapy achieved a five-year overall survival rate of 90.9%, compared with 81% for those receiving conventional photon radiation therapy. In oncology, a nearly ten-percentage-point survival difference over five years represents a meaningful clinical outcome.

Beyond survival, the proton cohort experienced lower rates of treatment-related complications. Difficulty swallowing, feeding tube dependence, dry mouth and severe decreases in immune cell counts were all reduced compared with traditional radiation therapy. These are not minor quality-of-life details; they influence how patients recover, tolerate additional treatments and maintain daily function after therapy.

Taken together, the results provide some of the strongest randomized evidence to date supporting proton therapy’s potential advantages for certain cancer populations.

Infrastructure Is Following Science

Clinical evidence of this magnitude often influences capital investment in healthcare infrastructure, and radiation oncology is beginning to reflect that shift.

In March 2026, the Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, part of Baptist Health, announced plans to open a new proton therapy center later this year. The facility is expected to expand access to precision radiation treatment across Palm Beach County.

Physicians involved in the program noted that having both proton and photon radiation therapy available under one roof allows oncologists to tailor treatment plans to each patient’s anatomy, cancer stage and long-term risk profile. In many cases, proton therapy may provide an additional layer of protection for nearby organs such as the heart, spinal cord or salivary glands.

As more clinical data emerges and hospitals evaluate long-term patient outcomes, access to proton therapy is increasingly viewed as part of the evolving toolkit of modern radiation oncology.

LIXTE and the LiGHT System: Positioned at the Intersection

LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT), headquartered in Boca Raton, Florida, spent 2025 expanding its presence across multiple segments of oncology innovation.

The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (“PP2A”). Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. By inhibiting PP2A, the compound stimulates cell-cycle progression and interferes with DNA repair in cancer cells, potentially making tumors more responsive to chemotherapy and immunotherapy. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with significant unmet medical need, including ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma.

In November 2025, LIXTE expanded beyond drug development through the acquisition of Liora Technologies Europe Ltd., now operating as a subsidiary of LIXTE and the developer of the LiGHT System, an electronically controlled proton therapy platform. Unlike conventional proton systems that rely on large cyclotrons or synchrotrons, electronically controlled accelerator technologies aim to improve flexibility and potentially reduce the infrastructure footprint associated with proton therapy facilities.

For LIXTE, the acquisition creates strategic optionality: participation in the expanding proton therapy ecosystem while continuing to advance a pharmaceutical pipeline designed to enhance the effectiveness of existing cancer treatments.

Convergence in the Next Phase of Oncology

The future of cancer treatment increasingly lies in integration rather than isolated breakthroughs. Precision radiation, immunotherapy, targeted drugs and advanced diagnostics are being combined in ways that were difficult to imagine even a decade ago.

Proton therapy’s emerging clinical evidence and expanding infrastructure reflect one side of that transformation. On the other, companies developing therapies designed to improve the effectiveness of existing treatments are exploring how those therapies may fit within a broader, multi-modal oncology ecosystem.

As these technologies continue to converge, the intersection between precision radiation and treatment-enhancing therapeutics may represent one of the more important frontiers in cancer care.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

• Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026.
• At the heart of the Zacks analysis is HyBryte(TM), which Soligenix is evaluating in the Phase 3 FLASH2 study for the treatment of CTCL.
• Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning and upcoming clinical catalysts, underscoring the potential value proposition for investors as Soligenix advances multiple programs toward key inflection points.

According to Zacks, Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026. Central to this outlook is the company’s ongoing Phase 3 FLASH2 trial evaluating HyBryte(TM) (“SGX301”), SNGX’s lead therapeutic candidate for the treatment of early-stage cutaneous T-cell lymphoma (“CTCL”). The report notes that an interim analysis is expected in the second quarter of 2026, with topline results anticipated later in the year, positioning the program as a near-term value driver for the company. 

At the heart of the Zacks analysis is HyBryte(TM), also known as SGX301 or synthetic hypericin, which Soligenix is evaluating in the confirmatory Phase 3 FLASH2 study for the treatment of CTCL. According to the report, the company had enrolled 66 of the planned 80 patients as of the latest update, and Zacks expects an interim analysis in the second quarter of 2026, followed by topline results in the second half of 2026. The report notes that the FLASH2 study is similar in design to the prior successful Phase 3 FLASH trial, but with an important difference: In FLASH2, patients receive 18 consecutive weeks of treatment before the primary efficacy endpoint is assessed, whereas the earlier trial measured the endpoint after the first six-week treatment cycle. 

One of the most notable points in the Zacks report is its discussion of the blinded aggregate response rate from FLASH2. Zacks says the overall blinded aggregate response rate remains consistent with what Soligenix reported in November 2025, at 48% for all patients who had completed the treatment phase of the study. That figure is materially higher than the 25% overall response rate used to design and power the trial, leading Zacks to say its confidence is high that the study will have a positive readout. The report goes further, explaining that if the placebo response rate is near the 10% rate used in the trial assumptions, then the active-treatment arm would likely need to be producing a very strong response to yield a combined blinded rate of 48%. Zacks does note that the exact numbers will not be known until the data are unblinded, but it views the update as a strong sign that the study is trending in the right direction.

Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease. Zacks highlights two recent regulatory developments. First, in February 2026, the European Medicines Agency’s Committee for Orphan Medicinal Products gave a positive recommendation on Soligenix’s request for orphan drug designation for SGX945 in Behçet’s disease, with European Commission ratification still pending. According to the report, orphan drug designation in the European Union would provide 10 years of marketing exclusivity following approval, along with other development-related incentives.

Second, the Zacks report reports that on March 10, 2026, the UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to SGX945 for Behçet’s disease. Zacks describes that designation as the initial step toward possible inclusion in the UK Early Access to Medicines Scheme, which is designed to help severely ill patients access promising therapies earlier than would otherwise be possible. These regulatory developments suggest that Zacks sees SGX945 as another meaningful value driver in the Soligenix pipeline.

The report also references SGX302, Soligenix’s psoriasis program. In its conclusion, Zacks says it expects updates in 2026 not only for the Behçet’s disease program with SGX945 but also for SGX302 following encouraging topline results from a phase 2a trial in mild-to-moderate psoriasis. That gives investors more than one clinical storyline to watch as the year unfolds.

On valuation, Zacks states that its $25 per share estimate is based on a probability-adjusted discounted cash flow model that incorporates potential future revenues from HyBryte, SGX302 and SGX945. The firm notes that the model is highly dependent on the continued clinical success of Soligenix’s pipeline and would be adjusted based on future clinical results.

Financially, the report’s projected financial tables show no product revenue contribution yet from HyBryte. The same tables include a “Public Health Solutions” line item, but there is no substantive discussion of that segment in the report’s narrative. That makes the main takeaway of this Zacks note clear: the report is primarily about Soligenix’s upcoming CTCL readouts, its Behçet’s disease regulatory momentum, and continuing advancement of its psoriasis program.

Overall, the Zacks Small-Cap Research report paints a picture of a company at an important inflection point. With several clinical catalysts on the horizon and a lead program that has already demonstrated encouraging efficacy signals, Soligenix is positioned to potentially deliver meaningful advancements in rare disease treatment while creating value for shareholders. As 2026 unfolds, the company’s progress in the clinic will likely remain a focal point for investors and industry observers alike, as Soligenix continues its efforts to bring innovative therapies to patients in need.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• The global service robotics market is projected to exceed $107 billion by 2030 as commercialization replaces experimentation
• TechForce Robotics delivers both TIM-E mobility robots and BIM-E beverage automation through a fully managed Robotics-as-a-Service Provider subscription model
• Modular transport systems and automated beverage platforms are designed for high-traffic, real-world hospitality and institutional environments

Autonomous-driven robotics is shifting from concept demonstrations to measurable operational deployment. As labor shortages and wage pressures persist across hospitality, healthcare and public venues, automation is increasingly viewed as infrastructure rather than innovation theater.

Nightfood Holdings Inc. (d.b.a. TechForce Robotics) (OTCQB: NGTF), is aligning with that transition by deploying both autonomous mobility platforms and automated beverage systems built for live, revenue-generating environments.

Commercialization Replaces Concept Robotics

Industry forecasts from multiple market research firms project the global service robotics market could surpass $107 billion by 2030, driven by adoption in hospitality, logistics, healthcare and entertainment. The primary driver is not technological curiosity but operational necessity. Facilities need systems that reduce repetitive labor and fill in gaps, all while maintaining consistency, throughput and safety.

Within this shift, the distinction between pilot programs and scalable deployment is becoming clearer. Robots must operate reliably in crowded spaces, integrate with existing workflows and demonstrate clear economic value.

TechForce Robotics has structured its approach around that deployment-first philosophy.

TIM-E: A Scalable Platform for Physical Movement

TIM-E (pronounced “Timmy”) is TechForce’s modular autonomous service robot designed to move items efficiently across large, complex facilities. Delivered through a Robotics-as-a-Service Provider subscription structure, TIM-E integrates hardware, navigation software, deployment mapping, support and ongoing optimization into a single managed solution.

Rather than deploying separate machines for each task, TIM-E supports modular attachments that allow one platform to handle luggage transport, linen movement, waste collection, housekeeping supply runs, concession support and secure locked-cart workflows. This flexibility enables facilities to adjust automation as operational demands evolve without replacing core infrastructure.

The system is engineered for active environments. According to TechForce materials, robots use LiDAR-based SLAM navigation, depth sensing, RGB cameras and layered sensor systems to operate safely around guests and staff. Precision mapping and dynamic routing allow units to adjust when hallways become congested, while elevator integration enables multi-floor operation.

The focus is not experimental autonomy but consistent back-of-house execution in real facilities.

BIM-E: Automated Beverage Service at Scale

Complementing mobility automation, TechForce also deploys BIM-E, an automated beverage dispensing system designed for high-traffic service environments. Like TIM-E, BIM-E is delivered through the company’s subscription-based Robotics-as-a-Service Provider framework, delivering consistent pours of beer, wine, coffee, kombucha, seltzer, and other beverages.

BIM-E is built to automate beverage pours with consistency and speed, maintaining throughput during peak demand in hotels, casinos, convention centers and restaurants. The system emphasizes repeatable precision to reduce waste and variability, while freeing staff to focus on guest interaction rather than repetitive pouring tasks.

The company notes that one bartender can manage multiple BIM-E units simultaneously, reflecting the broader industry push toward workforce-supportive automation rather than workforce replacement. POS integration and compatibility with various beverage types including beer, wine, coffee and specialty drinks allow the system to adapt across service environments.

By pairing physical mobility automation with beverage service automation, TechForce is building an ecosystem approach rather than a single-product strategy.

Robotics-as-a-Service Redefines Adoption

A central feature of TechForce’s commercialization strategy is its Robotics-as-a-Service Provider model. Instead of requiring capital purchases and long procurement cycles, automation is delivered as an operating expense subscription that includes deployment, mapping, maintenance, software updates and 24/7 monitoring.

Facilities can scale fleets up or down, modify attachments and adjust workflows as operational conditions change. This flexibility mirrors the broader evolution of enterprise technology adoption, where subscription infrastructure replaced capital-intensive ownership.

The RaaSP framework lowers financial barriers while aligning recurring revenue with ongoing service and optimization.

From Tools to Infrastructure

The broader robotics industry appears to be entering a stage where commercialization metrics matter more than prototype novelty. Real-world reliability, subscription economics and integration into daily workflows are becoming defining characteristics of market leaders.

By combining TIM-E’s modular mobility platform with BIM-E’s automated beverage service, both delivered through a managed subscription model, TechForce Robotics is positioning its portfolio within that infrastructure phase of service automation.

As industries continue to prioritize operational consistency, labor efficiency and scalable deployment, the movement from experimentation to execution may define the next chapter of service robotics adoption.

For more information, visit the company’s website at TechForceRobotics.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

Disseminated on behalf of ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) and may include paid advertising.

• ESGold Corp., a development-stage company committed to the acquisition, exploration, and development of high-quality mineral properties, just announced the appointment of Jason Tong as its new CFO
• Mr. Tong will lend his experience spanning more than 15 years, equipping ESGold with the support needed for its next phase of growth
• Tong will be key in driving the company’s financial strategy as it transitions toward becoming a producing gold and silver company
  

ESGold (CSE: ESAU) (OTCQB: ESAUF), a development-stage company committed to acquiring, exploring, and developing high-quality mineral properties worldwide, just announced the appointment of Mr. Jason Tong, CPA, CA, CFA, as the company’s Chief Financial Officer (“CFO”), effective immediately. Mr. Tong takes over from Mr. Tony Giuliano, and will play an integral role as the company transitions from development to production at its flagship Montauban Gold-Silver project (https://ibn.fm/0HcCq).

“Jason joins ESGold at a pivotal stage in the company’s evolution,” noted Gordon Robb, ESGold’s CEO. “Jason’s experience working with publicly listed companies and his deep understanding of capital markets, financial reporting, and corporate governance make him an excellent addition to our leadership team as we continue building ESGold into a producing mining company,” he added (https://ibn.fm/IGMmL).

Mr. Tong brings 15 years of experience, previously serving as CFO for Pathway Capital Ltd., a venture capital firm that manages a portfolio of early-stage companies with market capitalizations ranging from $5 million to $100 million. He also has experience working with publicly listed companies across the Nasdaq, TSX, and TSXV exchanges, serving in senior financial leadership and advisory roles in the mining, venture capital, and finance sectors.

With Mr. Tong’s addition, the company is set to realize their Montauban property’s full potential as it moves to production and further exploration. “We are assembling the operational and financial framework required to support ESGold’s next phase of growth, including production, expansion, or exploration activities, and continued engagement with the capital markets. Jason’s appointment represents another important step in that process,” Mr. Robb noted (https://ibn.fm/IGMmL).

This appointment follows the recent closing of its brokered LIFE offering, which raised gross proceeds of C$7.2 million. The offering involved the sale of 10,683,000 units of the company at C$0.68 per share, with proceeds to be used to advance the Montauban project and for general working capital and corporate purposes (https://ibn.fm/VMNYy). Mr. Tong’s oversight will ensure accountability for these proceeds, enabling the company to achieve both its short- and long-term objectives with the Montauban property.

“I am pleased to be joining ESGold at such an exciting time in the company’s development. With a fully permitted project, a clear path toward production, and expanding exploration potential at Montauban, ESGold is entering an important stage of growth,” noted Mr. Tong. “I look forward to working with the management team and Board to support the company’s financial strategy as it transitions toward becoming a producing gold and silver company,” he added (https://ibn.fm/IGMmL).

For company information, visit the company’s website at www.ESGold.com.

NOTE TO INVESTORS: The latest news and updates relating to ESAUF are available in the company’s newsroom at https://ibn.fm/ESAUF

• Safe Pro recently announced that it has completed the company’s participation in a recent U.S. Army event where soldiers used Safe Pro’s AI tools in real-world operational environments.
• Safe Pro’s patented Safe Pro Object Threat Detection (“SPOTD”) drone imagery analysis platform was used by soldiers to identify ground-based threats during day and night exercises.
• The threat data collected was also used by the company’s edge-based Navigation, Observation & Detection Engine (“NODE”) to create 2D/3D terrain maps and digital surface models to inform route and mission planning.

Safe Pro Group (NASDAQ: SPAI), a developer of AI-powered defense, security, and situational awareness solutions, recently announced that the company has completed its participation in the U.S. Army Transforming in Contact (“TiC”) 2.0 Autonomous Breach (https://ibn.fm/Tndrj) event.

At the event, Safe Pro’s patented AI tools were successfully used in real-world operational environments by command personnel and soldiers throughout the two-week-long exercise that took place at Ford Hood in Texas.

The U.S. Army wants to put $1 billion into TiC 2.0 to sponsor and fund the equipping and testing of advanced technology like drones mission planning technologies, directly with soldiers. During the recent invite only event, participating teams were given a chance to demonstrate and integrate their technologies with a group of soldiers.

For Safe Pro, the company’s Safe Pro Object Threat Detection (“SPOTD”) AI-powered drone imagery analysis platform was used by soldiers operating and training in the field. During the exercises, soldiers relied on the company’s AI tools day and night to quickly identify ground-based threats in drone images, including mines, barbed wire, obstacles, and fortifications.

This AI platform is capable of detecting and identifying more than 150 types of landmines and unexploded ordnance (“UXO”) and has been deployed in Ukraine for nearly three years, and is supported by a dataset that features over 2.4 million analyzed images. The technology also has identified over 45,600 threats, and covered around 29,900 acres of land.

In addition to simply identifying these threats, threat detections and related location data were integrated into situational awareness and mission planning tools including soldier-carried devices running the Tactical Awareness Kit (“TAK”) and General Dynamics Mission Systems’ GeoSuite. Also, the threat and obstacle data was also processed by Safe Pro’s edge-based Navigation, Observation & Detection Engine (“NODE”) to create 2D/3D terrain maps and digital surface models used by command personnel to inform both mission and route planning.

Speaking about the company’s participation in the event, Safe Pro Chairman and CEO, Dan Erdberg, said “We are thankful for the opportunity to participate in the Army’s TiC 2.0 and were thrilled to see how quickly our AI tools were successfully utilized by soldiers to provide actionable intelligence and battlefield situational awareness.”

He also added that “Our performance at TiC 2.0 has resulted in a significant expansion of our pipeline, driving multiple new capability requests from the Army personnel in attendance. Our teams are working diligently to support these requests as momentum continues to build for our technology within the Army.”

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group Inc. is a mission-driven tech company that delivers advanced AI-powered security and defense solutions to customers in the defense, homeland security, humanitarian, and law enforcement industries. At the core of Safe Pro’s mission is the company’s computer vision software technology that’s used to rapidly detect small objects in drone footage.

For more information, visit the company’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at  https://ibn.fm/SPAI

• The company has introduced a Self-Service Mortgage Experience (“SSME”) allowing borrowers to review loan customized scenarios and lock rates online without speaking to a loan officer.
• The feature provides a 24/7 digital mortgage pathway, reflecting growing demand for self-directed financial services among Millennials and Gen Z.
• Beeline’s AI-powered platform processes applications in seconds and presents personalized mortgage rate options rather than static rate quotes.
• The company’s broader digital infrastructure enables loan closings in 14–21 days, significantly faster than the traditional mortgage timeline.
• The platform targets two major demographic opportunities: younger homebuyers an investors seeking entry into property markets, plus older homeowners accessing home equity.

Beeline Holdings (NASDAQ: BLNE),  a fast-growing digital mortgage platform redefining the path to homeownership, announced the launch of a new automated lending pathway designed to streamline the home financing process. The company recently introduced its Self-Service Mortgage Experience (“SSME”), a platform feature that allows borrowers to explore customized loan options, model mortgage scenarios and lock interest rates entirely online. According to a company announcement, the first phase of the feature launched on March 11 and is currently available to roughly half of conventional mortgage applicants using Beeline’s platform (https://ibn.fm/ekxEb).

The feature reflects a broader shift across financial services as consumers increasingly expect digital-first experiences similar to those offered by technology platforms. In the mortgage sector, where loan approvals and document processing have historically involved multiple intermediaries and extended timelines, companies are investing heavily in automation to reduce friction.

Beeline’s platform allows borrowers to complete several steps of the mortgage process independently. After submitting an application through the company’s digital portal, the system processes borrower data and produces customized loan rate options within seconds. Borrowers can then explore scenarios and request a rate lock at any time. The system operates continuously, giving customers the option to progress through early stages of the mortgage process without waiting for business hours or scheduling a call with a loan officer. A digital assistant known as “Bob” is embedded in the platform to answer questions during the process. Borrowers can still connect with Beeline loan specialists if they prefer human guidance.

Jess Kennedy, chief operating officer of Beeline Financial Holdings, Beeline’s principal operating subsidiary, said the platform was designed to give borrowers greater transparency earlier in the lending process. “Customers can review potential loan scenarios and request a rate lock when they’re ready—on their own timetable—while still having the ability to connect with a Loan Guide whenever they want support,” Kennedy said.

The rollout is the first stage of a broader development roadmap intended to digitize additional parts of the mortgage process. Borrowers on the platform already complete steps such as signing disclosures, uploading documentation and paying for appraisals online. Future iterations are expected to allow borrowers to complete even more of the mortgage workflow independently.

The initiative comes as demographic shifts reshape the housing market. Millennials and members of Generation Z have become a growing share of mortgage applicants, yet homeownership rates for those cohorts remain below earlier generations. According to analysis cited by the company, about 26.1% of Gen Z adults and roughly 54.9% of Millennials owned homes in 2024, a modest increase from the previous year. Limited access to mortgages has been cited as a key barrier for younger buyers, according to reporting from National Mortgage Professional (https://ibn.fm/d0OKI). Beeline is positioning its digital mortgage tools partly as a response to that challenge.

The company says its AI-based underwriting engine can provide applicants with a preliminary qualification decision in approximately seven to eight minutes, offering borrowers a clearer understanding of their financing prospects early in the process. That capability is expected to appeal particularly to gig-economy workers and self-employed borrowers, whose income patterns often complicate traditional mortgage underwriting. Beyond first-time homebuyers, the platform is also targeting younger investors interested in acquiring rental properties. Beeline reports that a meaningful share of its loan originations support buyers purchasing investment real estate.

By lowering friction in the mortgage process, the company aims to make property investment more accessible to younger borrowers who may otherwise face barriers when navigating conventional lending systems. At the same time, the platform is designed to address a separate demographic opportunity among older homeowners. Many baby boomers hold substantial equity in their homes after decades of price appreciation.

Industry estimates suggest U.S. homeowners collectively hold roughly $10 trillion in home equity, creating demand for financial products that allow older borrowers to access that capital without selling their properties. Beeline has developed a range of lending and home-equity products to serve that segment.

The company operates through its primary lending subsidiary, Beeline Loans Inc., and also runs Beeline Title, an integrated closing and settlement services provider. Together, these operations form what the company describes as an end-to-end digital mortgage ecosystem.

Automation plays a central role in that system. Beeline’s proprietary production engine, known as Hive, manages much of the loan workflow, enabling the company to complete mortgage closings in approximately 14 to 21 days. That timeframe is significantly shorter than the traditional industry average, which can exceed a month. By expanding the number of mortgage steps borrowers can complete independently, the company is attempting to reduce costs, shorten timelines and provide customers with more control over the financing process.

For more information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

The relationship between growth companies and the capital markets has rarely been static. Periods of economic expansion often reward bold innovation and aggressive scaling, while more disciplined market environments place greater emphasis on operational execution, capital efficiency, and strategic clarity. As markets continue to recalibrate following several years of volatility and shifting interest-rate expectations, the dialogue between investors and emerging growth companies has become increasingly focused on fundamentals.

That evolving conversation will be front and center at the 38th Annual ROTH Conference, taking place March 22–24, 2026, in Dana Point, California. The event is expected to bring together approximately 500 public and private companies across a broad range of sectors, including consumer, technology and media, sustainability, industrial growth, AgTech, energy, metals and mining, healthcare, services, and insurance.

Industry gatherings have long played an important role in the growth-company ecosystem, but their function has evolved alongside the market itself. Investors today are increasingly focused on identifying companies capable of translating innovation into durable operating performance. For management teams, that means demonstrating not only the strength of their market opportunity, but also the discipline behind their capital allocation and long-term strategy.

The structure of the Roth Conference reflects this dynamic. In addition to company presentations, the program features industry panels, analyst-led fireside chats, and structured one-on-one and small-group meetings between investors and corporate leadership. These formats allow participants to move beyond headline narratives and engage in deeper conversations about strategy, sector trends, and the broader forces shaping the growth-company landscape.

Another defining characteristic of the event is the diversity of industries represented. Bringing together companies from multiple sectors creates opportunities for investors to identify emerging themes and cross-industry trends that may not be visible within a single vertical. For executives, it provides valuable perspective on how capital is flowing across different parts of the innovation economy.

Equally important are the connections formed through direct interaction. One-on-one meetings between investors and management teams remain one of the most effective ways to build long-term capital relationships, particularly in the small- and mid-cap universe where understanding leadership and strategy can be just as important as analyzing financial performance.

As the growth-company landscape continues to evolve, events like the Roth Conference serve as an important forum for these conversations. By bringing together investors, corporate leaders, and industry experts in a single setting, the conference provides a platform where new ideas are exchanged, relationships are formed, and the next generation of market leaders begins to take shape.

For companies navigating today’s capital markets, and for investors seeking the next wave of innovation, the discussions taking place in Dana Point this March are likely to offer valuable insight into where the growth economy is headed next. For more information on the conference, visit www.Roth.com/38thAnnualConference.

• Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.
• The UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to Soligenix’s SGX945 (dusquetide) for the treatment of Behçet’s disease.
• The recent designation in the United Kingdom builds on other regulatory recognitions previously granted to dusquetide.

Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet medical needs, recently received such recognition as its investigational therapy SGX945 was granted Promising Innovative Medicine (“PIM”) designation by the United Kingdom’s (“UK’s”) Medicines and Healthcare products Regulatory Agency (“MHRA”).

Designations granted by leading regulatory agencies play a critical role in advancing drug-development programs. These recognitions often signal that a therapy shows potential to address serious conditions where few treatment options exist. According to the UK MHRA, the PIM designation is awarded to medicines that appear to offer a major advantage over existing treatment options or benefit patients who currently have no adequate therapy available. The designation serves as an early step in the UK’s Early Access to Medicines Scheme, which was created to help patients with life-threatening or seriously debilitating conditions gain access to promising treatments before full marketing authorization.

Programs such as the Early Access to Medicines Scheme reflect a broader global effort among regulators to accelerate development pathways for therapies that address urgent medical needs. Regulatory agencies, including the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency, have developed similar initiatives designed to encourage innovation while maintaining safety standards. The FDA’s accelerated approval and breakthrough therapy pathways, for example, are intended to speed the development of drugs that treat serious diseases and fill an unmet medical need. These programs recognize that patients with severe or rare conditions often cannot wait for the traditional timelines associated with drug development.

Such designations are particularly important in the rare-disease sector, where patient populations are small and the scientific challenges are often complex. The World Health Organization notes that rare diseases collectively affect an estimated 300 million people worldwide. Because most rare diseases still lack approved treatments, regulatory frameworks that encourage innovation and accelerate access to promising therapies have become essential components of modern drug development.

Soligenix’s recent regulatory milestone reflects this global environment of collaboration between biotechnology innovators and health authorities. Earlier this month, the company announced that  the UK MHRA granted PIM designation to its SGX945 (dusquetide) for the treatment of Behçet’s disease. This designation recognizes the therapy’s potential to address a serious condition with limited treatment options and represents an important step toward possible inclusion in the Early Access to Medicines Scheme.

SGX945 is an injectable formulation of the innate defense regulator, dusquetide, designed to modulate the body’s natural immune response, help to balance inflammation, enhance pathogen clearance and support tissue healing. This approach represents a novel strategy for treating inflammatory and immune-related disorders, particularly those involving chronic or dysregulated innate immune responses. 

The therapy is being developed to treat Behçet’s disease, a rare and incurable inflammatory disorder that causes blood vessel inflammation throughout the body. The condition can produce recurring symptoms including painful oral and genital ulcers, skin lesions and inflammation affecting multiple organ systems. Because Behçet’s disease can significantly impact quality of life and may lead to serious complications, the development of new therapies remains an important focus within rare disease medicine.

Clinical data highlight the potential of SGX945 in addressing these symptoms. In a phase 2a pilot study involving patients with Behçet’s disease, treatment with SGX945 demonstrated improvements in oral ulcer outcomes, with positive responses observed in seven of eight treated patients. The therapy was also reported to be well tolerated in the study, with no treatment-related adverse events observed during the trial period.

The recent designation in the UK builds on other regulatory recognitions previously granted to dusquetide. The therapy has received fast track and orphan drug designations from the FDA for Behçet’s disease, reflecting the therapy’s potential importance in treating a rare condition with limited available treatment options. 

In addition, earlier this year, the European Medicines Agency Committee for Orphan Medicinal Products provided a positive recommendation on the company’s request for orphan drug designation with the next step in the process being ratification of the positive opinion by the European Commission. Such designations can provide incentives that support continued clinical development, including regulatory guidance and potential market exclusivity benefits once a therapy is approved.

Soligenix continues to advance a diversified pipeline built around its specialized biotherapeutics platform. The company’s programs target rare inflammatory conditions, oncology indications such as cutaneous T-cell lymphoma and additional infectious disease applications. By leveraging its scientific platforms and focusing on diseases with limited therapeutic options, the company seeks to develop innovative treatments that address areas of significant unmet medical need.

The PIM designation granted to SGX945 represents another step forward in that strategy. As regulatory agencies around the world work to accelerate the development of therapies for serious and rare conditions, recognitions such as this help signal scientific progress while opening pathways that may ultimately bring new treatment options more quickly to patients who currently have few alternatives.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX